Navigation Links
New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia
Date:7/25/2012

New Rochelle, NY, July 25, 2012A novel approach to gene therapy that instructs a person's own cells to produce more of a natural disease-fighting protein could offer a solution to treating many genetic disorders. The method was used to achieve a 2- to 3-fold increase in production of a protein deficient in patients with Friedreich's ataxia, as described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

The innovative gene therapy method described by Jacques Tremblay, Pierre Chapdelaine, Zo Coulombe, and Joel Rousseau, Laval University, Quebec, and University of Quebec, Canada, takes advantage of the ability of a family of proteins called Tal effector (TALE) proteins to target specific DNA sequences. As a model of how this method could be used to treat genetic disease, the authors engineered TALE proteins to target the gene that codes for the frataxin protein, which is deficient in Friedreich's ataxia. The ability to induce cells to produce more frataxin could reduce symptoms of the disease and provide an effective, long-term therapeutic strategy, conclude the authors in the article "TALE Proteins Induce the Expression of the Frataxin Gene. (http://online.liebertpub.com/doi/full/10.1089/hum.2012.034)

"This is a very clever approach to treat a recessive disease caused by decreased quantity of an otherwise normal protein," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>
Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... Now it's easy to make your RNA free of genomic DNA , ... , & Removal Reagents contain RNase-free DNase, ... to ensure safe, complete removal of , ... DNase Removal Reagent which, after digestion, eliminates DNase in , ...
... , ... RT-PCR and microarray gene expression analysis , ... no grinding or polytron required , ... tissue lysates , Faster and easier ...
... Low transfection efficiency and low cell , ... causes of unsuccessful gene , ... choosing the right transfection agent and transfection , ... in many cell types. Once a protocol is optimized ...
Cached Biology Technology:DNA-free A NEW Method to Remove DNA 2DNA-free A NEW Method to Remove DNA 3DNA-free A NEW Method to Remove DNA 4DNA-free A NEW Method to Remove DNA 5DNA-free A NEW Method to Remove DNA 6DNA-free A NEW Method to Remove DNA 7DNA-free A NEW Method to Remove DNA 8Hands-free Tissue Disruption No Homogenization Needed 2Hands-free Tissue Disruption No Homogenization Needed 3Hands-free Tissue Disruption No Homogenization Needed 4Hands-free Tissue Disruption No Homogenization Needed 5Hands-free Tissue Disruption No Homogenization Needed 6Hands-free Tissue Disruption No Homogenization Needed 7Optimizing siRNA Transfection for RNAi 2Optimizing siRNA Transfection for RNAi 3Optimizing siRNA Transfection for RNAi 4Optimizing siRNA Transfection for RNAi 5Optimizing siRNA Transfection for RNAi 6Optimizing siRNA Transfection for RNAi 7Optimizing siRNA Transfection for RNAi 8Optimizing siRNA Transfection for RNAi 9Optimizing siRNA Transfection for RNAi 10Optimizing siRNA Transfection for RNAi 11
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... There,s currently no reliable tool to help prosthetic developers ... medical personnel when bed-ridden patients need to be moved to ... now on the way. Prof. Amit Gefen of Tel Aviv ... a new device he calls the Soft Tissue Stress Monitor, ...
... and WEST PALM BEACH, Fla. , ... of authentication and endpoint protection solutions and ScriptRx, a ... Discharge Systems for Emergency Rooms and Urgent Care Centers, ... DigitalPersona into the ScriptRx System. Designed for these busy ...
... variant of a receptor in the brain,s reward circuitry ... dopamine is released in the brain following alcohol intake, ... National Institute on Alcohol Abuse and Alcoholism (NIAAA), part ... involved in transmitting the euphoria and other positive subjective ...
Cached Biology News:Finding the soft spot 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4Receptor variant influences dopamine response to alcohol 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
Yeast tRNA 50 l...
...
... Low volume pipetting is increasingly ... volumes in DNA sequencing and other ... with performance and precision unparalleled in ... documented confirmation of all aspirated,and dispensed ...
Biology Products: